AbbVie Advancing Rinvoq to Phase 3 Studies in Vitiligo
October 12 2023 - 6:29AM
Dow Jones News
By Colin Kellaher
AbbVie on Thursday said it is moving its blockbuster immunology
drug Rinvoq into Phase 3 studies in vitiligo after a successful
Phase 2b study in the chronic skin condition.
The North Chicago, Ill., biopharmaceutical company said the
Phase 2b study evaluating Rinvoq in adults with non-segmental
vitiligo met the primary endpoint of percent change from baseline
in a key scoring index at week 24 compared with placebo, adding
that the percent reduction at week 52 was greater than results at
week 24.
AbbVie said no new safety signals were identified in the study,
and that based on the data, it is advancing Rinvoq into Phase 3
studies in vitiligo, for which there are currently no approved
systemic treatment options.
AbbVie is counting on Rinvoq and the blockbuster psoriasis drug
Skyrizi to help make for lost sales for its mega-blockbuster
Humira, the highest-grossing drug of all time, which faces new
competition from copycats after patent expirations.
AbbVie is targeting combined 2025 risk-adjusted sales for Rinvoq
and Skyrizi of more than $17.5 billion and combined peak sales for
the two drugs topping $21 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 12, 2023 06:14 ET (10:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024